Ada Health Cockpit - March 2026
AbbVie Inc. (NYSE: ABBV) is a global research-driven biopharmaceutical company headquartered at 1 North Waukegan Road, North Chicago, Illinois. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie operates in over 70 countries with a workforce exceeding 50,000 employees worldwide. The company focuses on discovering and delivering innovative medicines across immunology, oncology, neuroscience, eye care, and aesthetics.
For fiscal year 2025, AbbVie reported total net revenues of $61.2 billion (up 8.6% reported, 8.5% operational), with adjusted diluted EPS of $10.00 and GAAP diluted EPS of $2.36. The company exceeded initial guidance by over $2 billion despite approximately $16 billion in U.S. Humira erosion from biosimilar competition.
AbbVie has successfully navigated the Humira biosimilar cliff, demonstrating exceptional portfolio resilience through next-generation immunology assets. Skyrizi (IL-23 inhibitor) and Rinvoq (JAK inhibitor) generated combined sales of $25.9 billion in 2025—surpassing the company's 2027 target early and exceeding peak Humira sales by over $4.5 billion.
The neuroscience portfolio delivered $10.8 billion (up 19.6%), anchored by Vraylar ($3.6B) and Botox Therapeutic. Strategic diversification via the 2020 Allergan acquisition ($63B) and 2024 Cerevel Therapeutics acquisition ($8.7B) positions AbbVie for sustained growth across multiple therapeutic areas.
AbbVie was spun off from Abbott Laboratories on January 1, 2013, as an independent biopharmaceutical company focused on research-based pharmaceuticals, while Abbott retained diagnostics, medical devices, nutritionals, and generics businesses. The separation, announced in 2011, allowed each entity to pursue distinct strategic priorities in an evolving healthcare landscape.
Trading commenced on the New York Stock Exchange (ticker: ABBV) on January 2, 2013, with AbbVie valued at approximately $55.5 billion at $35.12 per share on debut. Richard A. Gonzalez served as AbbVie's founding Chairman and CEO, emphasizing the company's robust portfolio and pipeline potential in immunology and virology.
| Year | Milestone | Details |
|---|---|---|
| 2013 | IPO & Independence | AbbVie begins trading (NYSE: ABBV); initial market cap ~$55.5B |
| 2015 | Pharmacyclics Acquisition | $21 billion acquisition for Imbruvica (ibrutinib), outbidding J&J |
| 2016 | Humira Patent Expiry (Primary, U.S.) | Primary patent expires, but AbbVie secures ~250 secondary patents delaying biosimilars until 2023 |
| 2018 | Humira LOE (Europe) | Biosimilars launch in EU following October 16, 2018 patent expiry |
| 2019 | Allergan Acquisition Announced | $63 billion deal for Botox, aesthetics, neuroscience assets |
| 2020 | Allergan Acquisition Completed | Closed May 8, 2020; projected >$2B annual synergies by year three |
| 2023 | Humira Biosimilar Launch (U.S.) | Eight biosimilars enter U.S. market starting January 31, 2023 |
| 2024 | Leadership Transition | Robert A. Michael becomes CEO (June 2024), succeeding Richard Gonzalez |
| 2024 | Cerevel Acquisition | $8.7B acquisition closes August 1 for neuroscience pipeline |
| 2025 | Skyrizi + Rinvoq Milestone | Combined sales reach $25.9B, exceeding 2027 target and surpassing peak Humira |
AbbVie Inc. is a publicly traded company listed on the New York Stock Exchange (ticker: ABBV) with approximately 1.77 billion shares outstanding. Institutional investors collectively own between 70-77% of AbbVie's outstanding shares, with approximately 4,500+ institutional holders.
| Shareholder | Ownership % | Shares (millions) | Holdings Value |
|---|---|---|---|
| Vanguard Group Inc. | 10.22% | 180.78 | Not disclosed |
| BlackRock Inc. | 8.53% | 150.83 | Not disclosed |
| State Street Corp | Not disclosed | Not disclosed | $14.85B |
| Geode Capital Management LLC | Not disclosed | Not disclosed | $7.24B |
| Capital Research Global Investors | Not disclosed | Not disclosed | $6.04B |
AbbVie's board consists of 13 members, with a strong majority of independent directors. Roxanne S. Austin serves as Lead Independent Director (appointed 2024, the first new Lead Independent Director since AbbVie's 2013 inception).
Start Date as CEO: June 2024
Start Date as Chairman: July 1, 2025
Robert Michael has over 32 years with AbbVie and its predecessor Abbott Laboratories. His career progression includes Chief Financial Officer (2018), Vice Chairman of Finance and Commercial Operations (2021), Vice Chairman and President (2022), Chief Operating Officer, and President and COO before becoming CEO. He succeeded Richard A. Gonzalez, who retired as CEO on July 1, 2024, served as Executive Chairman through June 30, 2025, and fully retired from the board effective July 1, 2025.
Tenure: 3.8 years in CFO role (as of early 2026)
Responsibilities: Oversees global manufacturing, supply chain, quality assurance, and related operational services
Note: Public sources do not provide comprehensive LinkedIn profiles or detailed career histories for most EVPs. AbbVie's official leadership page confirms executive names and general responsibilities but lacks granular biographical details for most roles below CEO/COO.
AbbVie's portfolio spans five primary therapeutic areas: Immunology, Oncology, Neuroscience, Eye Care, and Aesthetics.
| Product | Revenue (FY 2025) | Growth (YoY) | Patent/Exclusivity | Peak Sales Potential |
|---|---|---|---|---|
| Skyrizi (risankizumab) | $17.56B | +50% (2024); +31.9% Q4 | Mid-2030s (estimated) | >$25B |
| Rinvoq (upadacitinib) | $8.30B | +39% (2024); +28.6% Q4 | US: April 2037 | >$15B |
| Humira (adalimumab) | $4.54B | -49.5% | US LOE Jan 2023; EU Oct 2018 | Peak achieved (~$21B) |
| Imbruvica (ibrutinib) | ~$3.0B (est.) | Declining (-23% proj. 2026) | US: Patent expiry 2026 | Peak achieved (~$5-6B) |
| Venclexta (venetoclax) | ~$2.7-2.9B | +8.5% (Q2); +7.1% (Q3) | Mid-2030s (estimated) | $3-5B |
| Product | Revenue (FY 2025) | Growth (YoY) | Patent/Exclusivity | Peak Sales Potential |
|---|---|---|---|---|
| Vraylar (cariprazine) | $3.62B | +11% | US: 2030 | $4-5B |
| Botox (total) | ~$6.0B | Cosmetic softer Q3 | IRA negotiation pending | Current levels |
| Aesthetics Portfolio | $4.86B | -6.1% | Various; competitive pressure | $5-6B stabilization |
| Restasis | $1.19B | -33% | Generic competition | Declining |
| Lumigan/Ganfort | $267M | Flat YoY | Mature; generics | Current levels |
Based on earnings calls, press releases, and 2026 guidance, CEO Robert A. Michael and AbbVie leadership emphasize the following five drugs as strategic priorities:
2025 Revenue: $17.56 billion (+50% YoY)
2026 Projection: ~$21.5 billion (+20% growth)
Skyrizi is AbbVie's flagship immunology asset, having surpassed Humira peak sales in 2025. Leadership highlights its "best-in-class" efficacy and safety profile across psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. The drug's rapid adoption in IBD indications is a key 2026 growth driver.
2025 Revenue: $8.30 billion (+39% YoY)
2026 Projection: ~$10.1 billion (+22% growth)
Rinvoq's six-indication label (RA, PsA, AS, Crohn's, UC, atopic dermatitis) provides diversification and resilience. CEO Michael emphasizes Rinvoq's "strong momentum" in IBD and dermatology markets, with the April 2037 patent extension (secured September 2025) de-risking long-term growth.
2025 Revenue: $3.62 billion (+11% YoY)
2026 Projection: Included in $12.5 billion neuroscience portfolio (16% growth)
Vraylar is AbbVie's leading neuroscience revenue driver pre-Cerevel assets. Leadership highlights steady prescription growth and durable patent protection (to 2030). The drug's efficacy in both manic and depressive bipolar episodes differentiates it from competitors with narrower labels.
2024 Revenue: ~$6.0 billion combined (Therapeutic ~$3.3B; Cosmetic ~$2.7B)
2026 Guidance: Raised on Botox recovery
Botox remains a cash-generating pillar with dual therapeutic/cosmetic applications. CEO Michael notes efforts to "stabilize and grow" the aesthetics business post-2025 softness, with Botox Therapeutic providing counter-cyclical stability.
2025 Revenue: ~$2.7-2.9 billion (Q2: $691M +8.5%; Q3: $726M +7.1%)
Venclexta anchors AbbVie's oncology franchise alongside Imbruvica (declining) and emerging assets (Elahere, Teliso-V). Leadership emphasizes combination strategies (e.g., Venclexta + acalabrutinib sNDA for CLL) and durable remissions in AML.
Data Gap: AbbVie does not publicly disclose the names of business unit P&L owners or franchise leads for its therapeutic areas (immunology, oncology, neuroscience, aesthetics). The most senior publicly identified leaders with potential franchise oversight include:
Note: LinkedIn profiles for current franchise heads are not publicly available. For confirmed names and contacts, consult AbbVie's internal directories or investor relations directly.
AbbVie's pipeline emphasizes late-stage assets in oncology (solid tumors, blood cancers), neuroscience (Parkinson's disease, schizophrenia, mood disorders), and immunology label expansions.
| Asset | Mechanism | Indication(s) | Phase | Expected Readout / Notes |
|---|---|---|---|---|
| Telisotuzumab vedotin (EMRELIS™) | c-Met ADC | NSCLC (c-Met+), colorectal, pancreatic cancer | Phase 3 confirmatory; approved May 2025 | Phase 3 data expected 2026-2027 |
| Elahere (mirvetuximab) | FRα ADC | Platinum-sensitive ovarian cancer, frontline ovarian | Phase 3 trials initiating late 2025 | Approved April 2025 in platinum-resistant setting |
| Epcoritamab | CD3xCD20 bispecific | Relapsed/refractory follicular lymphoma | Phase 3 (EPCORE FL-1) | Reduced disease progression risk by 79% (ASH 2025) |
| Tavapadon | Dopamine D1/D5 partial agonist | Parkinson's disease | Phase 3 | Met primary endpoint; FDA submission planned 2025 |
| Emraclidine | M4 muscarinic PAM | Schizophrenia (discontinued); Alzheimer's (ongoing) | Phase 2 | Failed schizophrenia (Nov 2024); $3.5B impairment |
| Darigabat | GABAA PAM | Treatment-resistant epilepsy, panic disorder | Phase 2 | Ongoing; part of Cerevel portfolio |
Data Gap: AbbVie does not publicly disclose detailed revenue breakdowns by geography (U.S., Europe, Asia, etc.) in its 2025 financial reports. The following table presents available data with appropriate caveats.
| Geography | 2024 Revenue | 2025 Revenue | % of Total (Estimated) |
|---|---|---|---|
| United States | ~$43B | Not disclosed | ~60-70% (estimated/derived) |
| International | Not disclosed | Not disclosed | ~30-40% (estimated/derived) |
| Global Total | ~$56.3B | $61.2B | 100% |
Note: All international estimates are labeled as "estimated/derived" based on historical trends and partial 2024 data. Official 2025 geographic splits are not publicly available.
Primary Competitors:
The immunology market is shifting toward IL-23 inhibitors (Skyrizi, Tremfya) and JAK inhibitors (Rinvoq) as TNF inhibitors face biosimilar erosion. Skyrizi's $17.6B in 2025 positions AbbVie as the IL-23 leader.
Blood Cancers: AstraZeneca (Calquence), BeiGene (Brukinsa), Roche (Venclexta partner), Genmab (epcoritamab partner)
Solid Tumors: Daiichi Sankyo/AstraZeneca (Enhertu, $4B+), Gilead (Trodelvy), GSK (Zejula), AstraZeneca (Lynparza), Merck (Keytruda)
Atypical Antipsychotics: Otsuka/Lundbeck (Rexulti), generics (olanzapine, quetiapine)
Migraine: Eli Lilly (Emgality), Amgen/Novartis (Aimovig)
Skyrizi faces competition from J&J's Tremfya and Eli Lilly's Taltz. Oncology ADCs compete with Daiichi Sankyo's Enhertu ($4B+) and Gilead's Trodelvy. Aesthetics market share eroding to Galderma, Evolus, and Merz.
Cerevel portfolio: Emraclidine's Phase 2 schizophrenia failure resulted in $3.5B impairment. Tavapadon's Phase 3 success is critical. Oncology confirmatory trials (Teliso-V, Elahere) required for sustained launches.
| Metric | 2026 Guidance | Long-Term (Through 2029) |
|---|---|---|
| Total Revenue | $67B (+9.5%) | High single-digit CAGR (7-9%) |
| Adjusted EPS | $14.37-$14.57 | Sustained growth |
| Skyrizi | ~$21.5B | >20% annual growth through 2029 |
| Rinvoq | ~$10.1B | >20% annual growth through 2029 |
| Neuroscience | $12.5B (+16%) | Tavapadon approval, Botox stabilization |
| Company | Market Cap (2025/26) | 2025 Revenue | Forward P/E (Est.) |
|---|---|---|---|
| AbbVie | $401-414B | $61.2B | ~15-16x |
| Johnson & Johnson | $366.71B | ~$85B (pharma ~$50B) | ~14-16x |
| Merck | $201.3B | ~$65B | ~12-14x |
| Eli Lilly | Not specified | ~$35B | ~40-50x (GLP-1 premium) |
AbbVie trades at a premium to Merck and Gilead (15-16x P/E vs. 10-14x), reflecting strong Skyrizi/Rinvoq growth momentum and successful Humira transition. AbbVie trades at a discount to Eli Lilly (15-16x vs. 40-50x), as Lilly's obesity/diabetes portfolio commands biotech-like multiples.
| Product | Primary Indication(s) | US Exclusivity | EU Exclusivity | Key Risk |
|---|---|---|---|---|
| Humira | RA, Crohn's, UC, psoriasis | LOE Jan 2023 | LOE Oct 2018 | Biosimilar erosion to $3-4B by 2027 |
| Skyrizi | Psoriasis, PsA, Crohn's, UC | Mid-2030s (est.) | Mid-2030s (est.) | Competitive threat from Tremfya, Taltz |
| Rinvoq | RA, PsA, AS, Crohn's, UC, AD | April 2037 | Earlier (not disclosed) | JAK inhibitor class warnings |
| Imbruvica | CLL, SLL, MCL | 2026 expiry | 2026 expiry | Rapid generic erosion; next-gen BTKis |
| Venclexta | CLL, AML | Mid-2030s (est.) | Mid-2030s (est.) | Competitive BCL-2 programs |
| Vraylar | Schizophrenia, bipolar I | 2030 | 2030 (est.) | Generic competition post-2030 |
| Botox | Migraine, spasticity, aesthetics | IRA negotiation 2028 | Mature product | IRA pricing cuts; biosimilars internationally |
This section evaluates AbbVie's drug portfolio through the lens of Ada Patient Finder, a digital health solution that identifies undiagnosed patients and navigates them to care. The analysis focuses on drugs where:
| Drug / Indication | Ada Fit Score | Per-Patient Net Revenue (US) | Diagnostic Delay | Ada Fee Opportunity |
|---|---|---|---|---|
| Skyrizi (Psoriasis, PsA, Crohn's, UC) | 9/10 | $40K-70K | 3-15 months (IBD); 3x longer (minorities, psoriasis) | $50M-$1.86B |
| Rinvoq (RA, PsA, AD, IBD) | 8/10 | $35K-63K | 1-3 years (RA); adult AD underdiagnosed | $101M-$1.86B |
| Elahere (Ovarian Cancer) | 6/10 | $50K-105K | 1.1-7.75 months | $1.2M-$25.2M |
| Botox (Chronic Migraine) | 5/10 | $4K-8.4K | Underdiagnosis (21% diagnosed) | $6.9M-$240M |
Fit Score: 9/10
Over 600,000 Americans live with undiagnosed psoriasis, and racial minorities wait up to three times longer for diagnosis than white patients—facing a 112% higher underdiagnosis risk. In inflammatory bowel disease, nearly half of patients endure diagnostic delays exceeding 12 months for Crohn's disease or 6 months for ulcerative colitis, often misdiagnosed as IBS or gastritis, leading to preventable complications and higher treatment costs.
Skyrizi's $17.6 billion franchise spans these underserved populations, with Ada Patient Finder uniquely positioned to surface these chronic, symptom-rich conditions through skin lesion patterns, GI red flags, and musculoskeletal overlap—accelerating diagnosis and capturing 8-12% of first-year revenue per patient navigated to care. At 15,500-38,700 addressable psoriasis patients alone, this represents a $50M-$278M annual opportunity for Ada, with exponential scaling across Crohn's, UC, and PsA indications where diagnostic delays and underdiagnosis exceed 25-50%.
Fit Score: 8/10
Rheumatoid arthritis patients face diagnostic delays averaging 1-3 years, with up to 48% misdiagnosed before rheumatologist consultation—often as gout or undifferentiated arthritis—costing 46% more when diagnosed late in seropositive cases. In atopic dermatitis, 26% of cases are adult-onset and frequently misdiagnosed due to atypical hand/foot or facial presentations, leaving millions of adults undertreated.
Rinvoq's $8.3 billion franchise spans these high-delay conditions, with Ada Patient Finder surfacing classic musculoskeletal patterns (symmetric swelling, morning stiffness), dermatologic red flags (pruritus, flexural eczema), and GI symptoms. Atopic dermatitis alone represents 36K-288K addressable patients, translating to $101M-$1.86B in Ada fees at 8-12% first-year revenue—scaling exponentially across RA, PsA, and IBD indications.
| Drug | Fit Score | Reason for Exclusion |
|---|---|---|
| Humira | 3/10 | Declining franchise; biosimilar competition; low per-patient revenue |
| Imbruvica | 4/10 | Asymptomatic early CLL; incidental lab-driven diagnosis |
| Venclexta | 4/10 | CLL asymptomatic; AML hyper-acute; poor symptom fit |
| Vraylar | 3/10 | Low per-patient revenue ($6K-14K); psychiatric symptoms require clinical interview |
| Aesthetics Portfolio | 1/10 | Elective, patient-initiated; no diagnostic delay |
| Eye Care | 2/10 | Low per-patient revenue; screening-based diagnosis |
Total Ada Fee Opportunity Range: $151M - $3.95B annually
Primary Therapeutic Focus:
Strategic Recommendation: Prioritize immediate launch with Skyrizi and Rinvoq across autoimmune conditions where diagnostic delays (3-15 months IBD; 1-3 years RA) and underdiagnosis rates (25-50%) create substantial unmet need. Ada's symptom assessment engine is exceptionally well-suited to surface chronic inflammatory conditions with rich symptom profiles (GI bleeding, joint swelling, skin lesions, pruritus) and clear red flags that differentiate from benign conditions.
Note: Full reference list (98 sources total) available in the markdown report. For brevity, first 5 shown here.